Paper1698529
Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin.
Sadek H and 8 others. Cancer, 1990. Cited by 130 papers, by iCite.
Cite this record
ConductScience Library. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Papers, record 1698529. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1698529
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Lip Neoplasms | Major topic |
| Skin Neoplasms | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Bleomycin | |
| Child | |
| Cisplatin | |
| Combined Modality Therapy | |
| Female | |
| Fluorouracil | |
| Humans | |
| Male | |
| Middle Aged |
Source PubMed
Cited by52
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 130 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41514559 | Systemic Chemotherapy in Penile Squamous Cell Carcinoma: Mechanisms, Clinical Applications, and Evidence-Based Regimens. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41514559 | PubMed |
| 41252099 | Perioperative Systemic Therapy for High-Risk Cutaneous Squamous Cell Carcinoma. | Am J Clin Dermatol | 2026 | https://conductscience.org/library/papers/41252099 | PubMed |
| 41228268 | Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228268 | PubMed |
| 40405694 | Cetuximab plus 5-fluorouracil in patients with advanced cutaneous squamous cell carcinoma: a retrospective cohort study. | J Dtsch Dermatol Ges | 2025 | https://conductscience.org/library/papers/40405694 | PubMed |
| 39682109 | The Role of Radiation, Immunotherapy, and Chemotherapy in the Management of Locally Advanced or Metastatic Cutaneous Malignancies. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39682109 | PubMed |
| 38500295 | Neoadjuvant Chemotherapy Alone or Combined with EGFR-Directed Targeted Therapy or Anti-PD-1 Immunotherapy for Locally Advanced Lacrimal Sac and Nasolacrimal Duct Carcinomas. | Semin Ophthalmol | 2024 | https://conductscience.org/library/papers/38500295 | PubMed |
| 37780565 | Treatment of metastatic squamous cell carcinoma arising in sacrococcygeal pilonidal sinus: a case report series. | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/37780565 | PubMed |
| 37747408 | Squamous cell carcinoma of the eyelid. | Jpn J Clin Oncol | 2024 | https://conductscience.org/library/papers/37747408 | PubMed |
| 37686588 | Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37686588 | PubMed |
| 37370790 | Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37370790 | PubMed |
| 36991168 | Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma. | Ann Surg Oncol | 2023 | https://conductscience.org/library/papers/36991168 | PubMed |
| 36329570 | Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta-analysis. | Skin Res Technol | 2023 | https://conductscience.org/library/papers/36329570 | PubMed |
| 35954316 | Advances in Cutaneous Squamous Cell Carcinoma Management. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35954316 | PubMed |
| 35760499 | Metastatic insidious super giant basal cell carcinoma. | BMJ Case Rep | 2022 | https://conductscience.org/library/papers/35760499 | PubMed |
| 35158818 | Recent Advanced in the Treatment of Advanced SCC Tumors. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35158818 | PubMed |
| 35070956 | Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives. | Front Oncol | 2021 | https://conductscience.org/library/papers/35070956 | PubMed |
| 34877077 | Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma. | Dermatol Pract Concept | 2021 | https://conductscience.org/library/papers/34877077 | PubMed |
| 34842930 | Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany. | Acta Derm Venereol | 2022 | https://conductscience.org/library/papers/34842930 | PubMed |
| 34195900 | High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Clinical Review. | Ann Surg Oncol | 2021 | https://conductscience.org/library/papers/34195900 | PubMed |
| 34122442 | Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient. | Front Immunol | 2021 | https://conductscience.org/library/papers/34122442 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1698529
GET https://conductscience.org/api/papers/v1/1698529/cited_by?page=2